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Abstract
Traumatic brain injury (TBI) is a major environmental risk factor for Alzheimer’s disease. Intracellular accumulations of
amyloid-b and tau proteins have been observed within hours following severe TBI in humans. Similar abnormalities have
been recapitulated in young 3xTg-AD mice subjected to the controlled cortical impact model (CCI) of TBI and sacrificed at
24 h and 7 days post injury. This study investigated the temporal and anatomical distributions of amyloid-b and tau
abnormalities from 1 h to 24 h post injury in the same model. Intra-axonal amyloid-b accumulation in the fimbria was
detected as early as 1 hour and increased monotonically over 24 hours following injury. Tau immunoreactivity in the fimbria
and amygdala had a biphasic time course with peaks at 1 hour and 24 hours, while tau immunoreactivity in the
contralateral CA1 rose in a delayed fashion starting at 12 hours after injury. Furthermore, rapid intra-axonal amyloid-b
accumulation was similarly observed post controlled cortical injury in APP/PS1 mice, another transgenic Alzheimer’s disease
mouse model. Acute increases in total and phospho-tau immunoreactivity were also evident in single transgenic TauP301L
mice subjected to controlled cortical injury. These data provide further evidence for the causal effects of moderately severe
contusional TBI on acceleration of acute Alzheimer-related abnormalities and the independent relationship between
amyloid-b and tau in this setting.
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Introduction
Moderate to severe traumatic brain injury (TBI) can accelerate
cognitive decline and increases the risk of dementia of the
Alzheimer’s type [1,2,3,4,5]. Alzheimer’s disease (AD) is charac-
terized by several pathological hallmarks, including tau-containing
neurofibrillary tangles and neuritic plaques composed of the
amyloid-b (Ab) peptides [6]. There has been robust evidence
linking TBI to AD-related pathologies. Intracellular accumulation
of Ab, extracellular deposition of diffuse Ab plaques, and
aggregation of tau have been observed in humans, sometimes
within hours post severe injury [7,8,9,10,11,12,13]. Therefore,
TBI is hypothesized to be causally related to acceleration of AD-
related pathologies. Rotational head injury in pigs [14] and our
recent findings in young 3xTg-AD mice subjected to CCI support
this hypothesis [15]. Specifically, we found intra-axonal Ab
accumulation and accelerated tau pathology in these mice at 1
day and 7 days post TBI. There has been some controversy about
whether the intracellular immunoreactivity using certain antibod-
ies represents Ab vs. APP [16]. Our immunostaining using several
antibodies including 3D6 established that this post-injury axonal
immunoreactivity was specific for Ab [15], as 3D6 does not
recognize APP [17]. The questions of whether Ab and tau
pathologies are altered within hours post TBI and whether the
findings in 3xTg-AD mice can be generalized remained to be
investigated. In the current study, we show that Ab accumulation
is observed as early as 1 hour post injury in 3xTg-AD mice, and
the temporal pattern of Ab accumulation is distinct from those of
tau abnormalities. Additionally, we demonstrate that CCI also
causes acute Ab accumulation in young APP/PS1 mice [18],
which harbor a different PS1 mutation from 3xTg-AD mice, and
acutely accelerates tau pathology in TauP301L transgenic mice
[19]. Overall, our CCI model represents a useful tool for future
investigation into the link between TBI and AD.
Results
Acute axonal Ab pathology post CCI in 3xTg-AD mice
Axonal Ab pathology is a characteristic feature of human
traumatic axonal injury [9,13,20]. To model this pathology, we
employed CCI TBI on young 3xTg-AD mice, which express
mutant forms of human amyloid precursor protein (APP), presenilin
1 (PS1) and tau [21,22]. By staining the brains of injured and age-
matched, uninjured 3xTg-AD mice with severaldifferent antibodies
specific for Ab, we have previously shown that this injury paradigm
caused intra-axonal Ab accumulation at 24 h post TBI [15].
We analyzed Ab axonal pathology with HJ3.4 antibody against
Ab1–13 in these studies. To demonstrate that HJ3.4 does not
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Western blot analysis. Identical aliquots (100 mg) from brain
lysates of a 9 month-old 3xTg-AD mouse were immunoprecipi-
tated with monoclonal HJ3.4, 82E1, 6E10 antibodies, or no
primary antibody control. Monoclonal 82E1 has been previously
shown to be specific for Ab [16,23], while monoclonal 6E10
antibody can recognize both Ab and APP [16]. The resultant
immunodepleted supernatants were subjected to Western blotting
with 6E10 antibody. Our data demonstrated that HJ3.4 antibody,
similar to 82E1 antibody, does not immunoprecipitate APP
(Figure 1A).
When we stained the brains of injured and sham 3xTg-AD mice
which were sacrificed at 24 hours post injury with HJ3.4 antibody,
we observed that the fimbria/fornix, a white matter region
vulnerable to axonal injury, exhibited the most prominent axonal
Ab pathology (Figure 1B, D). This was consistent with our
previous findings using other anti-Ab antibodies [15]. Less
extensive but still clearly abnormal Ab accumulation was observed
in the ipsilateral hippocampal commissure (Figure 1F), corpus
callosum (Figure 1H), and external capsule (Figure 1J) of injured
3xTg-AD mice. Ab was not immunohistochemically detected in
the corresponding white matter regions of age-matched, uninjured
3xTg-AD mice (Figure 1 C, E, G, I). No Ab staining was
observed in the ipsilateral CA1 of injured 3xTg-AD mice (data not
shown).
Since Ab accumulation has been detected as early as 2 h post
severe TBI in humans [7], we tested the hypothesis that TBI
causes very early axonal Ab accumulation in 3xTg-AD mice by
sacrificing independent groups of mice at 1, 6, 9, 12, and 24 h post
injury. We found Ab in injured axons at all time points following
injury (Figure 2). Morphologies of Ab-positive axonal varicosities
evolved from small swellings observed at 1 and 6 hours after injury
(Figure 2B–C) to larger spheroids, bulbs, and beaded varicose
fibers at the later times (9, 12, and 24 h post TBI, Figure 2D–F).
Stereological quantification revealed moderate numbers of injured
axons with Ab accumulation in some but not all mice at the
earliest time points examined (1 h and 6 h after injury,
Figure 2G). However, substantially greater numbers of Ab-
immunoreactive axonal varicosities were present at later time
points, and all mice sacrificed between 9 and 24 hours had this
pathology (9, 12, and 24 h, Figure 2G). The increase in Ab-
positive axonal varicosities between 6 and 9 hours after TBI was
statistically significant, as was the increase between 12 and
24 hours (Figure 2G,p ,0.05).
In summary, CCI TBI consistently accelerated Ab axonal
accumulation in young 3xTg-AD mice. Ab accumulation
appeared as early as 1 h post TBI, and continued to rise through
24 h.
Ab accumulation in APP/PS1 mice
To test whether the findings of acute Ab accumulation post TBI
in 3xTg-AD mice can be generalized to another mouse model, we
subjected a different transgenic line, APP/PS1 mice to CCI of
similar injury severity. These mice overexpress the Swedish
(K670M/N671L) mutation of the human APP gene and the
human PS1 gene with exon 9 deleted [18]. They were injured at 2
months of age; extensive extracellular Ab pathology normally
develops by approximately 6 months of age in this line. They were
sacrificed at 24 h post TBI; their brains were stained for APP to
assess the extent of axonal injury, and for Ab using two different
Figure 1. Controlled cortical impact (CCI) causes intra-axonal
Ab accumulation in young 3xTg-AD mice at 24 hours. A.
Immunoprecipitation (IP) and Western blot (WB) showed that HJ3.4
antibody, similar to 82E1 antibody, did not recognize APP, while, 6E10
antibody recognized APP. B. Representative Cresyl violet stained
sections showing white matter regions (boxes) with positive axonal
Ab pathology following TBI in 3xTg-AD mice (Modified from [46]). C–J.
HJ3.4 staining in uninjured (sham) and injured (CCI) 3xTg-AD mice,
counterstained with Cresyl violet. Intra-axonal Ab accumulation was
observed in the ipsilateral fimbria (C–D, black box in B), ipsilateral
hippocampal commissure (E–F, blue box in B), ipsilateral corpus
callosum (G–H, red box in B) and ipsilateral external capsule (I–J,
purple box in B) of injured 3xTg-AD mice. Scale bar in C:5 0mm. Most
prominent Ab staining was observed in the ipsilateral fimbria/fornix of
injured mice. Ab staining has beads-on-a-string and varicose morphol-
ogies, consistent with morphologies of injured axons.
doi:10.1371/journal.pone.0025475.g001
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antibodies. TBI resulted in comparable degree of axonal injury in
pericontusional white matter in both APP/PS1 and 3xTg-AD
mice, as evidenced by similar patterns of APP staining
(Figure 3B–C). Stereological quantification of APP-positive
axonal varicosities corroborated the qualitative observation
(3xTg-AD: 295,579636,388 APP-positive axonal varicosities per
cubic mm, n=8 vs. APP/PS1: 272,212643,249, n=5, p=0.69).
Likewise, the pattern of Ab accumulation detected by panAb and
HJ3.4 antibodies appeared similar in injured 3xTg-AD and APP/
PS1 mice (Figure 3E–F, H–I). Quantification also confirmed this
histological finding (3xTg-AD: 65,43768,458 HJ3.4-positive
varicosities vs. APP/PS1: 47,257611,763, p=0.23). Uninjured
APP/PS1 mice at 2 months of age had neither APP nor Ab
accumulation in the ipsilateral fimbria/fornix (Figure 3A, D, G).
These data suggest post-traumatic Ab accumulation in 3xTg-AD
mice is not unique to the genetic constructs carried by these mice.
Anatomical and temporal patterns of tau accumulation
post CCI in 3xTg-AD mice
We have previously reported that CCI resulted in tau
accumulation at 24 h in several brain regions of injured 3xTg-
AD mice [15]. These were the ipsilateral fimbria/fornix, ipsilateral
amygdala, and contralateral (but not ipsilateral) CA1 (Figure 4A–
B). Total tau accumulated in puncta in the ipsilateral fimbria/
fornix. Perinuclear tau staining was observed in neurons of the
ipsilateral amygdala, while tau staining mostly localized to
neuronal processes of the contralateral CA1.
Here, we investigated the temporal patterns of tau accumulation
in these regions using the same mice used to assess the time course
of Ab described above. We quantitatively characterized the time
course of tau immunoreactive changes using stereological methods
(Figure 4I, P, W). In the ipsilateral fimbria, there were
significantly elevated numbers of tau-positive puncta at 1 h and
24 h, but not at 6 h–12 h following injury (Figure 4C–H). In
sham mice, there were 3,4206919, whereas at 1 h post injury,
there were 69,64168,496 (p,0.05) and at 24 h there were
138,887635,543 (p,0.0001) tau-stained puncta per cubic milli-
meter of fimbria (Figure 4I).
Tau immunoreactivity in cell bodies of the ipsilateral amygdala
exhibited a similar biphasic time course: the numbers of
immunoreactive cell bodies were increased at 1 h following injury
(Figure 4K), came back to sham levels from 6 h to12 h
(Figure 4L–N), and rose again at 24 h (Figure 4O). Since there
was substantial tau immunoreactivity in sham 3xTg-AD mice in
this region (Figure 4J), stereological quantification of numbers of
tau-positive somata was expressed as percent of sham. While
numbers of tau-positive cell bodies from 6 h to 12 h after injury
were similar to sham, significantly more were apparent at 1 h and
24 h in ipsilateral amygdala after injury (Figure 4P,p ,0.05).
Interestingly, the temporal profile of tau-positive processes in
the contralateral hippocampal CA1 region followed a different
pattern, with a delayed monophasic rise. Specifically, the extent of
tau immunoreactivity in contralateral CA1 in uninjured 3xTg-AD
mice and injured mice sacrificed from 1 h to 9 h following injury
appeared similar (Figure 4Q–T). From 12 h after TBI, however,
tau immunoreactivity in this region increased (Figure 4U–V).
Stereological quantification of total length of tau-positive process
using the spherical probes (also known as ‘spaceballs’) method
indicated a significant increase from sham starting at 12 h
following injury (Figure 4W,p ,0.05); this measure remained
elevated at 24 h (Figure 4V, W).
Thus, CCI increased tau immunoreactivity in a multifocal
fashion in the brains of 3xTg-AD mice. A two-phase increase in
tau immunoreactivity was observed at 1 hour and 24 hours after
TBI in the ipsilateral fimbria and ipsilateral amygdala, while only
a single phase was observed at 12–24 hours in the contralateral
hippocampal CA1 region. Notably, the anatomical and temporal
distribution of TBI-related changes in tau immunoreactivity was
distinct from those of post-injury Ab accumulation.
Increased tau immunoreactivity in TauP301L mice post CCI
To provide further evidence for the independent relationship
between Ab and tau in the setting of TBI, we performed CCI on
transgenic mice expressing only human tau mutant gene,
TauP301L[19]. Expression of the transgene in these mice was
under transcriptional control of the Thy1.2 promoter, the same
promoter which drives transgenes expression in 3xTg-AD mice.
Tau pathology was investigated at 24 h post TBI in 6 month old
TauP301L mice by immunohistochemistry with an antibody against
total human tau. We found that CCI also caused acute tau
accumulations with punctate morphologies in the ipsilateral
fimbria/fornix of injured TauP301L mice (Figure 5A–B). Quan-
tification indicated there were substantial numbers of tau-positive
puncta in the ipsilateral fimbria/fornix of injured TauP30L mice;
approximately half as many as in injured 3xTg-AD mice
(TauP301L: 63,18069,636 tau-positive puncta per cubic mm of
fimbria, n=6, vs. 3xTg-AD mice: 138,887635,543, n=8,
p=0.1). This result is not surprising, as the 3xTg-AD mice were
Figure 2. Intra-axonal Ab accumulation monotonically increas-
es from 1 to 24 hours post CCI in 3xTg-AD mice. A.A b staining
with biotinylated HJ3.4 antibody (against Ab1–13) in the ipsilateral
fimbria/fornix of a sham 3xTg-AD mouse. Sections were counterstained
with Cresyl violet. Scale bar: 50 mm. B–F.A b staining in the ipsilateral
fimbria/fornix of an injured 3xTg-AD mouse at 1 h (B), 6 h (C), 9 h (D),
12 h (E) and 24 h (F) after CCI. G. Stereological quantification of total
numbers of Ab-positive axonal varicosities as a function of time after
injury in 3xTg-AD mice. N=4–8 mice per group per time point. Bars
represent mean 6 SEM. One-way ANOVA with Newman-Keuls post
tests, # p,0.05, ## p,0.01: significant increase from injured mice
from previous time point. ** p,0.01, *** p,0.0001: significant increase
from sham mice at same time point.
doi:10.1371/journal.pone.0025475.g002
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were heterozygous. Furthermore, total tau staining in the
ipsilateral amygdala and contralateral CA1 of injured TauP301L
was increased relative to sham TauP301L mice, similar to the effects
in injured 3xTg-AD mice (Figure 5C–F vs. Figure 4O, V).
Since CCI acutely affects tau phosphorylation in 3xTg-AD mice
at several sites, specifically at Serine 199, Serine 396 and Serine
404, as detected with phospho-specific tau antibodies pS199 and
PHF1, respectively [15], we tested whether CCI increased tau
phosphorylation in injured TauP301L mice by staining with these
antibodies. Abnormal, punctate phospho-tau staining was ob-
served in the ipsilateral fimbria/fornix of injured but not uninjured
TauP301L mice (Figure 6A–D). Similar results were found in all 6
injured TauP301L mice.
In summary, controlled cortical impact TBI consistently
increased tau pathology in both young 3xTg-AD mice and
TauP301L mice. The anatomical and temporal pattern of tau
pathology was distinct from that of Ab.
Discussion
The current study shows that CCI TBI can cause rapid Ab
accumulation in injured axons of young 3xTg-AD mice. This
intra-axonal Ab was detectable at 1 hour post injury, and
continued to rise monotonically through 24 hours. Several brain
regions of injured 3xTg-AD mice also exhibited increased tau
immunoreactivity, but the time course was different across regions.
In particular, puntate tau staining the ipsilateral fimbria and
perinuclear tau staining in the amygdala had a biphasic response
with peaks at 1 hour and 24 hours post TBI. Instead, the numbers
of tau-positive processes in the contralateral CA1 started to
increase at 12 h post injury. However, total tau immunoreactivity
in the ipsilateral CA1 of 3xTg-AD mice was not significantly
affected by TBI. Neuronal damage to this region may have caused
release of tau into the extracellular space, where it could not be
detected by immunohistochemistry. Importantly, the finding of
post-traumatic Ab accumulation in 3xTg-AD mice was recapit-
ulated in a different transgenic mouse model of Alzheimer’s
disease, APP/PS1. Similarly,accelerated tau pathology in 3xTg-
AD mice was also observed in transgenic mice carrying only
TauP301L mutation at 24 hours following TBI.
We have previously presented evidence that CCI can
independently alter Ab and tau abnormalities in 3xTg-AD mice
[15]. Specifically, systemic inhibition of c-secretase activity, an
enzyme required for Ab generation from its precursor, APP,
successfully blocked post-traumatic Ab accumulation in injured
mice. However, tau pathology was unaffected following blockade
of Ab generation and accumulation. In the present study, we
found distinct anatomical and temporal patterns of Ab and total
tau abnormalities throughout 24 hours post TBI in 3xTg-AD
mice. Furthermore, we found abnormal total and phospho-tau
accumulation in injured axons, and increased somatic tau staining
in single-transgenic TauP301L mice subjected to TBI. Although the
temporal distribution of phospho-tau following acute TBI in 3xTg-
AD mice remains to be investigated, findings in this study add
additional support to the hypothesis that Ab and tau pathologies
are independent in the setting of TBI. As such, future studies will
be required to investigate the mechanisms underlying TBI-
induced tau hyperphosphorylation.
APP, the precursor protein of Ab, has been found to accumulate in
injured axons within 30 minutes following central nervous system
injury [24]. Axonal APP accumulation has in turn been hypothesized
to serve as substrate for intra-axonal Ab generation [20,25]. Thus,
our finding that intra-axonal Ab was detected starting at 1 hour post
TBI in 3xTg-AD mice is in line with the reported time for the earliest
APP accumulation following brain trauma.
Figure 3. Ab accumulates in fimbria/fornix axons of 2 month-old APP/PS1 mice at 24 hours post CCI. A–C. APP staining in the ipsilateral
fimbria/fornix of a sham APP/PS1 mouse (A), an injured APP/PS1 mouse (B), and an injured 3xTg-AD mouse (C). Scale bar: 50 mm. Similar extent of
axonal injury as detected by APP staining was seen in injured APP/PS1 and 3xTg-AD mice. D–F.A b staining with panAb antibody. G–I.A b staining
with HJ3.4 antibody. Histological and stereological quantification showed similar extent of Ab accumulation in injured APP/PS1 and 3xTg-AD mice:
47,257611,763 HJ3.4-positive varicosities per cubic mm in APP/PS1 (n=5) vs. 65,43768,458 in 3xTg-AD mice (n=8), Student’s t-test, p=0.23.
doi:10.1371/journal.pone.0025475.g003
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[26]. Additionally, transgenic mice which have both PS1
mutations and APP mutations exhibit accelerated Ab pathology
compared to those with only APP mutations [18,27,28,29,30,31].
In the setting of TBI, these mutations also appear necessary for
rapid intra-axonal Ab accumulations. Acute Ab accumulation in
axons of injured 3xTg-AD and APP/PS1 mice in the present study
and the lack of such pathology in previous experimental TBI
models using wildtype and mutant APP mice without PS1
mutations support this observation [32].
Our mouse model recapitulates one aspect of post-traumatic Ab
pathology in human TBI: intra-axonal Ab accumulation.Neitherour
model nor other small animal experimental TBI models of which we
are aware result in acute extracellular plaques. Interestingly, recent
findings suggest that intracellular Ab accumulation is an early event
in Alzheimer’s disease pathogenesis, preceding plaque formation
[33,34,35,36]. Indeed, animal and cellular Alzheimer models have
shown that the accumulation of intracellular Ab species are
neurotoxic and may be linked to synaptic dysfunction, cell loss, and
memory impairment [26,28,37,38,39]. Thus, our TBI mouse model
of intra-axonal Ab accumulation may emerge as an interesting model
to study the relationship between TBI and Alzheimer’s disease.
The biphasic increase in tau immunoreactivity following TBI in
ipsilateral fimbria and amygdala of 3xTg-AD mice is intriguing.
Figure 4. Time course of CCI-induced tau pathology is distinct in several brain structures of 3xTg-AD mice. Tau staining was with
polyclonal total tau antibody. A–B. Tau staining in a sham (A) and an injured (B) 3xTg-AD mouse. Three regions with accelerated tau pathology
compared to sham at 24 h post TBI were the ipsilateral fimbria/fornix (black box), ipsilateral amygdala (blue box), and contralateral CA1 (red box).
Scale bar: 2 mm. C–H. Higher magnification of punctate tau staining in the ipsilateral fimbria (black box in A–B) of a sham (C) and injured 3xTg-AD
mice at 1 h (D), 6 h (E), 9 h (F),12 h (G), and 24 h (H) following CCI. Scale bar in C: 50 mm. I. Stereological quantification of numbers of tau-positive
puncta per cubic millimeter in ipsilateral fimbria as a function of time post injury. J–O. Perinuclear, cytoplasmic tau staining in somata of the
ipsilateral amygdala (blue box in A–B). P. Stereological quantification of numbers of tau-positive somata per cubic millimeter in the ipsilateral
amygdala as a function of time post injury. Q–V. Tau staining in processes of the contralateral CA1 (red box in A–B). W. Stereologcial quantification
of tau-positive processes of CA1 pyramidal neurons per cubic millimeter as a function of time post injury. N=4–8 mice per group per time point. Bars
are mean 6 SEM in fimbria, and percent of sham 6 SEM for amygdala and CA1 region. One-way ANOVA with Newman-Keuls post tests, * p,0.05,
** p,0.01, *** p,0.001: significant increase from sham mice at same time point. # p,0.05: significant increase from injured mice at previous time
point.
doi:10.1371/journal.pone.0025475.g004
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reflect an immediate response to mechanical injury. Increased tau
immunoreactivity at 24 hours in this study, together with our
previous finding of persistent tau abnormalities at 7 days, suggests
initiation of secondary injury mechanisms induced by TBI.
However, our TBI mouse models have several limitations. First,
we utilized transgenic mice with mutations implicated in familial
dementia, while most humans with TBI are not genetically
predisposed to developing such Ab and tau pathologies.
Nevertheless, these mutations seem to be required for post-
traumatic human pathologies to be recapitulated in mice. Other
genetic differences between humans and mice may be one of the
underlying reasons. Second, the majority of brain injuries in
human are mild and diffuse [40], while our TBI model produces a
relatively severe, focal contusion with pericontusional axonal
injury. Thus, to generalize our findings, other TBI paradigms such
as fluid percussion injury and closed-skull impact, which result in
more diffuse axonal injury, will be required. Lastly, the current
study focuses only on the acute period post injury. Future studies
will therefore be required to assess the long-term effects of intra-
axonal buildup of Ab and tau on neuronal survival, synaptic
integrity, and behavioral outcomes following TBI in these mice.
In summary, our experimental TBI model using 3xTg-AD,
APP/PS1, and TauP301L mice confirms that moderately severe
CCI TBI can acutely accelerate intra-axonal Ab and tau
pathologies, and increase cytoplasmic tau accumulation. These
models may provide useful tools to study therapeutic strategies to
prevent adverse effects mediated by these pathologies following
brain injury.
Materials and Methods
Animals
We used 6 month old homozygous 3xTg-AD mice, 2 month old
heterozygous APPswe/PSEN1DE9 (APP/PS1) transgenic mice
(line 85, Stock number 004462, The Jackson Laboratory), and 6
month old heterozygous TauP301L mice. 3xTg-AD mice have
human PS1M146V gene knocked in to the mouse allele, overexpress
human APP Swedish gene and tauP301L gene [22]. 3xTg-AD mice
used for all experiments were derived from the original founders
received from the LaFerla lab in 2007. There was no evidence of
genetic drift over time. APP/PS1 mice overexpress human APP
Swedish gene and human PSEN1 with an exon 9 deletion [18].
TauP301L mice overexpress human tau gene with P301L mutation
[19]. Mice were housed in standard cages in 12 h light, 12 h dark
cycle and given food and water ad. lib. Mice of both sexes were
randomly assigned to experimental groups. All experiments were
approved by the animal studies committee at Washington
University in St Louis, animal welfare assurance number A-
3381-01.
Figure 5. CCI causes acute axonal tau accumulation and increases somatic tau staining in TauP301L mice. Polyclonal antibody against
total human tau was used for immunohistochemistry. A–B. Punctate tau staining in the ipsilateral fimbria of injured but not sham TauP301L mice.
Scale bar in A: 50 mm. C–D. Increased tau immunoreactivity in the cell bodies of the ipsilateral amygdala of injured compared to sham TauP301L mice.
E–F. Increased tau immunoreactivity in processes of the contralateral CA1 of injured compared to sham TauP301L mice.
doi:10.1371/journal.pone.0025475.g005
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The experimental TBI methods used in this study were
performed as described previously [41,42]. Briefly, following
craniotomy, experimental TBI was induced by impacting a
3.0 mm diameter metal tip onto the cortex (5 m/s, 100 ms dwell
time). A 2.0 mm impact below the dura was chosen for all
experiments, as this injury severity results in contusion in the
ipsilateral cortex and substantial damage to the underlying
hippocampus. Sham injured mice went through similar surgical
procedures but were not injured. Mice were kept at 37uC
throughout the procedure and allowed to recover on a warming
pad to prevent hypothermia-induced hyperphosphorylation of tau
[43].
Antibodies
Monoclonal HJ3.4 antibody (against Ab1–13) was a gift from Dr.
David Holtzman [44]. Monoclonal 82E1 antibody, which
recognizes free N-terminus of Ab [16,23], was purchased from
IBL-America (Minneapolis, MN). Monoclonal 6E10 antibody,
which recognizes both APP and Ab [16], was from Covance
(Princeton, NJ). Polyclonal APP, panAb (against Ab15–30), and
phospho-tau at S199 antibodies were purchased from Invitrogen
Corp. Polyclonal total tau antibody was from Pierce. Monoclonal
PHF1 antibody (against tau phosphorylated at S396 and S404)
was a gift from Dr. Peter Davies, Albert Einstein College of
Medicine [45]. HJ3.4 was biotinylated using commercially
available reagent from Pierce.
Immunoprecipitation and Western Blot
To verify the specificity of HJ3.4 for Ab over amyloid precursor
protein (APP), an immunodepletion assay was performed on brain
homogenate from a 9 month old 3xTg-AD mouse. Whole brain
was removed after transcardial perfusion with PBS containing
0.3% heparin and immediately dounce homogenized in RIPA
buffer (150 mM NaCl, 50 mM Tris-HCl, 1% Triton X-100,
0.10% SDS, 0.5% deoxycholic acid, 2.5 mM EDTA, pH 8.0)
containing protease inhibitor cocktail (Roche) at a 10:1 ratio
(RIPA volume/tissue weight) using 25 strokes followed by brief
sonication. The resulting homogenate was centrifuged for
20 minutes at 17,0006ga t4 uC to remove insoluble protein.
Total protein was determined using a standard BCA protein assay.
Individual aliquots containing 100 mg of homogenate were
immunodepleted using 10 mg of each antibody (HJ3.4, 82E1,
6E10). After overnight incubation, complexes were captured using
150 mg Protein-G DynabeadsH (#100.03D, Invitrogen). The
resulting immunodepleted supernatants were assayed by Western
blot, as described below, to determine affinity in solution for APP.
Samples for Western blot analysis were combined with standard
Laemmli buffer and heated to 85uC to denature for 5 minutes.
Protein samples were size separated on NuPAGEH 12% Bis-Tris
gels (Invitrogen) in 2-(N-morpholino)ethanesulfonic acid (MES)
SDS running buffer at 150 Volts. SeeBlueH Plus-2 prestained
standard (Invitrogen) was used to visualize and estimate the
progression and size of the sample migration. Gels were then
transferred to 0.2 mm nitrocellulose using Towbin buffer (25 mM
Tris, 192 mM glycine, pH 8.6) containing 20% methanol at
150 mA for 1 hour. For Ab western blotting, membranes were
incubated at 95uC for 1 minute in PBS to allow for improved
antigen binding and then cooled in room temperature PBS prior
to blocking. Membranes were blocked in 2% non-fat dry milk
(NFDM) PBS for 1 hour. Between all remaining steps, membranes
were washed 36for 10 minutes each with PBS-T (0.05% Tween
20). For detection of APP, the mouse monoclonal 6E10 was used
at 1 mg/mL in 2% NFDM PBS overnight at 4uC. Bound primary
antibodies were detected using a sheep anti-mouse-HRP
(#NA931V, GE Healthcare) at 50 ng/mL in 2% NFDM PBS
and then developed with ECL Advance Reagent (GE Healthcare)
followed by exposure to film emulsion.
Immunohistochemistry
Staining was done on 50 mm free-floating sections, as described
previously [15]. Primary antibodies were monoclonal HJ3.4
antibody (0.75 mg/ml), polyclonal rabbit anti panAb (1 mg/ml),
polyclonal rabbit anti APP (0.5 mg/ml), polyclonal sheep anti tau
(1 mg/ml), polyclonal rabbit anti pS199 (1 mg/ml), and monoclo-
nal PHF1 antibody (1:1000). Corresponding biotinylated second-
ary antibodies and Vectastain Elite strepavidin-biotin kit (Vector
Laboratories) were used for detection. 3-39diaminobenzidine
substrate was used for color development.
Stereology
All stereological quantifications were done via StereoInvestiga-
tor version 8.2 software, as previously described [15]. Quantifi-
cations were done such that the injury status and survival time post
injury were blinded to the experimenter. Optical fractionator
stereological method was used to estimate number of APP-, HJ3.4-,
and total tau-positive axonal bulbs in the ipsilateral fimbria and
tau-positive somata in ipsilateral amygdala. The spherical probes
(aka ‘‘space balls’’) method was used to estimate tau-positive
process length in the contralateral CA1 region. Parameters for
counting grids and counting frames were as previously reported
[15].
Statistical methods
All data were analyzed using Prism 5.0 (GraphPad Sofware,
Inc). For changes of either Ab or tau pathology as function of time,
one-way ANOVAs with Newman-Keuls post tests were used
because there were no prespecified hypotheses about the direction
of change. For pairwise comparisons of Ab immunohistochemical
data between injured 3xTg-AD and APP/PS1 mice, and of tau
immunohistochemical data between 3xTg-AD and TauP301L mice,
Figure 6. CCI affects tau phosphorylation in the ipsilateral
fimbria/fornix of TauP301L mice at 24 hours. A–B. Phospho-tau
staining using pS199 antibody against tau phosphorylated at S199.
Scale bar in A: 50 mm. C–D. Phospho-tau staining using PHF1 antibody
against tau phosphorylated at S396 and S404. Both phospho-tau
antibodies detect punctate axonal tau accumulations in the ipsilateral
fimbria of injured but not sham TauP301L mice.
doi:10.1371/journal.pone.0025475.g006
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SEM. Statistical significance was set at p,0.05.
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